
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
---|---|---|---|---|---|
SNY
Sanofi SA
|
$11.7B | $1.00 | -17.69% | 92.33% | $62.57 |
BNTX
BioNTech SE
|
$173.2M | -$2.26 | 23.21% | -34.69% | $136.68 |
BPMC
Blueprint Medicines
|
$171.3M | -$0.53 | 24.15% | -36.72% | $126.87 |
NVAX
Novavax
|
$149.2M | -$0.11 | -64.49% | -82.16% | $13.43 |
REGN
Regeneron Pharmaceuticals
|
$3.3B | $8.55 | -7.35% | -30.58% | $728.55 |
VIGL
Vigil Neuroscience
|
-- | -$0.47 | -- | -9.62% | $9.52 |
Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
---|---|---|---|---|---|---|---|
SNY
Sanofi SA
|
$48.55 | $62.57 | $118.7B | 17.32x | $2.20 | 4.52% | 2.49x |
BNTX
BioNTech SE
|
$111.00 | $136.68 | $26.7B | 191.55x | $0.00 | 0% | 9.00x |
BPMC
Blueprint Medicines
|
$129.36 | $126.87 | $8.4B | -- | $0.00 | 0% | 14.75x |
NVAX
Novavax
|
$6.97 | $13.43 | $1.1B | 2.63x | $0.00 | 0% | 0.95x |
REGN
Regeneron Pharmaceuticals
|
$570.59 | $728.55 | $61.6B | 14.53x | $0.88 | 0.31% | 4.62x |
VIGL
Vigil Neuroscience
|
$8.07 | $9.52 | $376.6M | -- | $0.00 | 0% | -- |
Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
---|---|---|---|---|
SNY
Sanofi SA
|
20.53% | -0.268 | 15.28% | 0.26x |
BNTX
BioNTech SE
|
1.53% | 1.572 | 1.45% | 9.86x |
BPMC
Blueprint Medicines
|
53.13% | 2.692 | 6.79% | 2.62x |
NVAX
Novavax
|
180.06% | 1.446 | 16.39% | 1.84x |
REGN
Regeneron Pharmaceuticals
|
6.33% | 0.047 | 2.89% | 3.90x |
VIGL
Vigil Neuroscience
|
-- | 10.653 | -- | -- |
Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
---|---|---|---|---|---|---|
SNY
Sanofi SA
|
$8.1B | $2.6B | 6.79% | 8.47% | 22.36% | $2.2B |
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
BPMC
Blueprint Medicines
|
$146.6M | -$41.1M | -23.09% | -49.13% | 12.78% | -$56.3M |
NVAX
Novavax
|
$612.2M | $515.5M | -- | -- | 83.91% | -$187.1M |
REGN
Regeneron Pharmaceuticals
|
$2.6B | $591.7M | 14.69% | 15.7% | 30.17% | $773.6M |
VIGL
Vigil Neuroscience
|
-- | -$23.5M | -- | -- | -- | -$24.2M |
BioNTech SE has a net margin of 17.65% compared to Sanofi SA's net margin of -227.46%. Sanofi SA's return on equity of 8.47% beat BioNTech SE's return on equity of -3.91%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
SNY
Sanofi SA
|
72.76% | $0.80 | $101.3B |
BNTX
BioNTech SE
|
54.16% | -$1.82 | $20.8B |
Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand BioNTech SE has an analysts' consensus of $136.68 which suggests that it could grow by 23.14%. Given that Sanofi SA has higher upside potential than BioNTech SE, analysts believe Sanofi SA is more attractive than BioNTech SE.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
SNY
Sanofi SA
|
5 | 3 | 0 |
BNTX
BioNTech SE
|
14 | 5 | 0 |
Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.318%.
Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Sanofi SA quarterly revenues are $11.2B, which are larger than BioNTech SE quarterly revenues of $192.3M. Sanofi SA's net income of $2B is higher than BioNTech SE's net income of -$437.5M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 9.00x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
SNY
Sanofi SA
|
2.49x | 17.32x | $11.2B | $2B |
BNTX
BioNTech SE
|
9.00x | 191.55x | $192.3M | -$437.5M |
Blueprint Medicines has a net margin of 17.65% compared to Sanofi SA's net margin of 0.33%. Sanofi SA's return on equity of 8.47% beat Blueprint Medicines's return on equity of -49.13%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
SNY
Sanofi SA
|
72.76% | $0.80 | $101.3B |
BPMC
Blueprint Medicines
|
98.13% | $0.01 | $729.9M |
Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.93%. Given that Sanofi SA has higher upside potential than Blueprint Medicines, analysts believe Sanofi SA is more attractive than Blueprint Medicines.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
SNY
Sanofi SA
|
5 | 3 | 0 |
BPMC
Blueprint Medicines
|
2 | 15 | 1 |
Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.
Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Sanofi SA quarterly revenues are $11.2B, which are larger than Blueprint Medicines quarterly revenues of $149.4M. Sanofi SA's net income of $2B is higher than Blueprint Medicines's net income of $496K. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 14.75x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
SNY
Sanofi SA
|
2.49x | 17.32x | $11.2B | $2B |
BPMC
Blueprint Medicines
|
14.75x | -- | $149.4M | $496K |
Novavax has a net margin of 17.65% compared to Sanofi SA's net margin of 82.81%. Sanofi SA's return on equity of 8.47% beat Novavax's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
SNY
Sanofi SA
|
72.76% | $0.80 | $101.3B |
NVAX
Novavax
|
97.75% | $2.93 | $94.5M |
Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 92.66%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
SNY
Sanofi SA
|
5 | 3 | 0 |
NVAX
Novavax
|
3 | 2 | 1 |
Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.
Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Sanofi SA quarterly revenues are $11.2B, which are larger than Novavax quarterly revenues of $626.3M. Sanofi SA's net income of $2B is higher than Novavax's net income of $518.6M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Novavax's PE ratio is 2.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 0.95x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
SNY
Sanofi SA
|
2.49x | 17.32x | $11.2B | $2B |
NVAX
Novavax
|
0.95x | 2.63x | $626.3M | $518.6M |
Regeneron Pharmaceuticals has a net margin of 17.65% compared to Sanofi SA's net margin of 26.7%. Sanofi SA's return on equity of 8.47% beat Regeneron Pharmaceuticals's return on equity of 15.7%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
SNY
Sanofi SA
|
72.76% | $0.80 | $101.3B |
REGN
Regeneron Pharmaceuticals
|
84.67% | $7.27 | $31.4B |
Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 27.68%. Given that Sanofi SA has higher upside potential than Regeneron Pharmaceuticals, analysts believe Sanofi SA is more attractive than Regeneron Pharmaceuticals.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
SNY
Sanofi SA
|
5 | 3 | 0 |
REGN
Regeneron Pharmaceuticals
|
14 | 7 | 0 |
Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.
Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Sanofi SA quarterly revenues are $11.2B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Sanofi SA's net income of $2B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Regeneron Pharmaceuticals's PE ratio is 14.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus 4.62x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
SNY
Sanofi SA
|
2.49x | 17.32x | $11.2B | $2B |
REGN
Regeneron Pharmaceuticals
|
4.62x | 14.53x | $3B | $808.7M |
Vigil Neuroscience has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Vigil Neuroscience's return on equity of --.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
SNY
Sanofi SA
|
72.76% | $0.80 | $101.3B |
VIGL
Vigil Neuroscience
|
-- | -$0.49 | -- |
Sanofi SA has a consensus price target of $62.57, signalling upside risk potential of 28.88%. On the other hand Vigil Neuroscience has an analysts' consensus of $9.52 which suggests that it could grow by 18.02%. Given that Sanofi SA has higher upside potential than Vigil Neuroscience, analysts believe Sanofi SA is more attractive than Vigil Neuroscience.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
SNY
Sanofi SA
|
5 | 3 | 0 |
VIGL
Vigil Neuroscience
|
0 | 8 | 0 |
Sanofi SA has a beta of 0.489, which suggesting that the stock is 51.088% less volatile than S&P 500. In comparison Vigil Neuroscience has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.52%. Vigil Neuroscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Vigil Neuroscience pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Sanofi SA quarterly revenues are $11.2B, which are larger than Vigil Neuroscience quarterly revenues of --. Sanofi SA's net income of $2B is higher than Vigil Neuroscience's net income of -$22.4M. Notably, Sanofi SA's price-to-earnings ratio is 17.32x while Vigil Neuroscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.49x versus -- for Vigil Neuroscience. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
SNY
Sanofi SA
|
2.49x | 17.32x | $11.2B | $2B |
VIGL
Vigil Neuroscience
|
-- | -- | -- | -$22.4M |
Signup to receive the latest stock alerts
If you know popular consumer appliance brands Shark and Ninja,…
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Market Cap: $4T
P/E Ratio: 56x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 34x
Veritex Holdings [VBTX] is down 3.26% over the past day.
Monopar Therapeutics [MNPR] is down 8.6% over the past day.
Nebius Group NV [NBIS] is up 2.98% over the past day.